{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:47:51Z","timestamp":1790401671127,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["Interagency Agreement (IAA) AID-GH-T-17-00002 between USAID and the Naval Medical Research Center."],"award-info":[{"award-number":["Interagency Agreement (IAA) AID-GH-T-17-00002 between USAID and the Naval Medical Research Center."]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>A DNA-prime\/human adenovirus serotype 5 (HuAd5) boost vaccine encoding<jats:italic>Plasmodium falciparum<\/jats:italic>(Pf) circumsporozoite protein (PfCSP) and Pf apical membrane antigen-1 (PfAMA1), elicited protection in 4\/15 (27%) of subjects against controlled human malaria infection (CHMI) that was statistically associated with CD8+ T cell responses. Subjects with high level pre-existing immunity to HuAd5 were not protected, suggesting an adverse effect on vaccine efficacy (VE). We replaced HuAd5 with chimpanzee adenovirus 63 (ChAd63), and repeated the study, assessing both the two-antigen (CSP, AMA1 = CA) vaccine, and a novel three-antigen (CSP, AMA1, ME-TRAP = CAT) vaccine that included a third pre-erythrocytic stage antigen [malaria multiple epitopes (ME) fused to the Pf thrombospondin-related adhesive protein (TRAP)] to potentially enhance protection.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methodology<\/jats:title><jats:p>This was an open label, randomized Phase 1 trial, assessing safety, tolerability, and VE against CHMI in healthy, malaria na\u00efve adults. Forty subjects (20 each group) were to receive three monthly CA or CAT DNA priming immunizations, followed by corresponding ChAd63 boost four months later. Four weeks after the boost, immunized subjects and 12 infectivity controls underwent CHMI by mosquito bite using the Pf3D7 strain. VE was assessed by determining the differences in time to parasitemia as detected by thick blood smears up to 28-days post CHMI and utilizing the log rank test, and by calculating the risk ratio of each treatment group and subtracting from 1, with significance calculated by the Cochran-Mantel-Haenszel method.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>In both groups, systemic adverse events (AEs) were significantly higher after the ChAd63 boost than DNA immunizations. Eleven of 12 infectivity controls developed parasitemia (mean 11.7 days). In the CA group, 15 of 16 (93.8%) immunized subjects developed parasitemia (mean 12.0 days). In the CAT group, 11 of 16 (63.8%) immunized subjects developed parasitemia (mean 13.0 days), indicating significant protection by log rank test compared to infectivity controls (p = 0.0406) and the CA group (p = 0.0229). VE (1 minus the risk ratio) in the CAT group was 25% compared to -2% in the CA group. The CA and CAT vaccines induced robust humoral (ELISA antibodies against CSP, AMA1 and TRAP, and IFA responses against sporozoites and Pf3D7 blood stages), and cellular responses (IFN-\u03b3 FluoroSpot responses to CSP, AMA1 and TRAP) that were not associated with protection.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrated that the ChAd63 CAT vaccine exhibited significant protective efficacy, and confirmed protection was afforded by adding a third antigen (T) to a two-antigen (CA) formulation to achieve increased VE. Although the ChAd63-CAT vaccine was associated with increased frequencies of systemic AEs compared to the CA vaccine and, historically, compared to the HuAd5 vectored malaria vaccine encoding CSP and AMA1, they were transient and associated with increased vector dosing.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0256980","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T17:24:50Z","timestamp":1631121890000},"page":"e0256980","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["A three-antigen Plasmodium falciparum DNA prime\u2014Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-na\u00efve adults"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-8924","authenticated-orcid":true,"given":"Marvin J.","family":"Sklar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santina","family":"Maiolatesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sedegah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Limbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimfa","family":"Teneza-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilin","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Monique","family":"Hollis-Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Glenna","family":"Banania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelese","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Ganeshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharina","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2343-3824","authenticated-orcid":true,"given":"Michael R.","family":"Hollingdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatalio","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Alcorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Garver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"Bankard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnel","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tida","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehkonti","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidhartha","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Tamminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Berrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Bittaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-9836","authenticated-orcid":true,"given":"Katie","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Diggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A.","family":"Soisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Villasante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Duplessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"pone.0256980.ref001","unstructured":"WHO: Malaria eradication: benefits, future scenarios and feasibility. Executive summary, WHO Strategic Advisory Group on Malaria Eradication. WHO\/CDS\/GMP\/201910 2019."},{"issue":"Suppl 4","key":"pone.0256980.ref002","doi-asserted-by":"crossref","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","article-title":"The march toward malaria vaccines","volume":"33","author":"SL Hoffman","year":"2015","journal-title":"Vaccine"},{"key":"pone.0256980.ref003","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults","volume":"6","author":"M Sedegah","year":"2011","journal-title":"PLoS One"},{"key":"pone.0256980.ref004","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","article-title":"Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component","volume":"6","author":"C Tamminga","year":"2011","journal-title":"PLoS One"},{"key":"pone.0256980.ref005","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4161\/hv.22129","article-title":"Clinical trial in healthy malaria-naive adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite\/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA","volume":"8","author":"TL Richie","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0256980.ref006","doi-asserted-by":"crossref","first-page":"e55571","DOI":"10.1371\/journal.pone.0055571","article-title":"DNA prime\/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity","volume":"8","author":"I Chuang","year":"2013","journal-title":"PLoS One"},{"key":"pone.0256980.ref007","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"GA O\u2019Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"pone.0256980.ref008","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"SH Hodgson","year":"2015","journal-title":"J Infect Dis"},{"key":"pone.0256980.ref009","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"DP Webster","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0256980.ref010","article-title":"Sterile Immunity to Hepatic Stage Malaria after DNA Prime\/Adenovirus Boost Immunization is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes","author":"M Sedegah","year":"2014","journal-title":"PLoS One"},{"key":"pone.0256980.ref011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1250672","article-title":"Immunology. Immune activation with HIV vaccines","volume":"344","author":"AS Fauci","year":"2014","journal-title":"Science"},{"key":"pone.0256980.ref012","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1189\/jlb.1A0813-451RR","article-title":"The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses","volume":"96","author":"JC Small","year":"2014","journal-title":"J Leukoc Biol"},{"key":"pone.0256980.ref013","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"N Tatsis","year":"2007","journal-title":"Blood"},{"key":"pone.0256980.ref014","doi-asserted-by":"crossref","first-page":"115ra112","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"S Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"pone.0256980.ref015","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"JE Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"pone.0256980.ref016","doi-asserted-by":"crossref","first-page":"e0233840","DOI":"10.1371\/journal.pone.0233840","article-title":"IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents","volume":"15","author":"B Hickey","year":"2020","journal-title":"PLoS One"},{"key":"pone.0256980.ref017","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"KJ Ewer","year":"2013","journal-title":"Nat Commun"},{"key":"pone.0256980.ref018","first-page":"29","article-title":"In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines","volume":"2","author":"RC Hedstrom","year":"1998","journal-title":"Int J Mol Med"},{"key":"pone.0256980.ref019","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1128\/IAI.73.5.2863-2872.2005","article-title":"Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites","volume":"73","author":"R Wang","year":"2005","journal-title":"Infect Immun"},{"key":"pone.0256980.ref020","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults","volume":"8","author":"C Ogwang","year":"2013","journal-title":"PLoS One"},{"key":"pone.0256980.ref021","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"SH Sheehy","year":"2011","journal-title":"Mol Ther"},{"key":"pone.0256980.ref022","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors","volume":"7","author":"SH Sheehy","year":"2012","journal-title":"PLoS One"},{"key":"pone.0256980.ref023","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"SH Sheehy","year":"2012","journal-title":"Mol Ther"},{"issue":"Suppl 2","key":"pone.0256980.ref024","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/infdis\/jiu063","article-title":"Controlled human malaria infection","volume":"209","author":"M Spring","year":"2014","journal-title":"J Infect Dis"},{"key":"pone.0256980.ref025","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(08)60418-3","article-title":"Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort","volume":"371","author":"TA Gaziano","year":"2008","journal-title":"Lancet"},{"key":"pone.0256980.ref026","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/mt.2014.157","article-title":"Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial","volume":"22","author":"SH Hodgson","year":"2014","journal-title":"Mol Ther"},{"key":"pone.0256980.ref027","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"SJ McConkey","year":"2003","journal-title":"Nat Med"},{"key":"pone.0256980.ref028","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","article-title":"A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults","volume":"1","author":"VS Moorthy","year":"2004","journal-title":"PLoS Med"},{"key":"pone.0256980.ref029","doi-asserted-by":"crossref","first-page":"e115161","DOI":"10.1371\/journal.pone.0115161","article-title":"A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS","volume":"9","author":"E de Barra","year":"2014","journal-title":"PLoS One"},{"key":"pone.0256980.ref030","article-title":"Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals","author":"SH Hodgson","year":"2014","journal-title":"J Infect Dis"},{"key":"pone.0256980.ref031","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"JA Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"pone.0256980.ref032","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.1986.35.66","article-title":"Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum","volume":"35","author":"JD Chulay","year":"1986","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0256980.ref033","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"MC Sprangers","year":"2003","journal-title":"J Clin Microbiol"},{"key":"pone.0256980.ref034","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"AS Ishizuka","year":"2016","journal-title":"Nat Med"},{"key":"pone.0256980.ref035","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"KE Lyke","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0256980.ref036","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria infection and immunogenicity study","author":"JA Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"pone.0256980.ref037","doi-asserted-by":"crossref","first-page":"e5254","DOI":"10.1371\/journal.pone.0005254","article-title":"Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A","volume":"4","author":"MD Spring","year":"2009","journal-title":"PLoS One"},{"key":"pone.0256980.ref038","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection","volume":"9","author":"C Tamminga","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0256980.ref039","article-title":"Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP","author":"T Rampling","year":"2016","journal-title":"J Infect Dis"},{"key":"pone.0256980.ref040","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.4049\/jimmunol.146.3.1020","article-title":"Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites","volume":"146","author":"Y Charoenvit","year":"1991","journal-title":"J Immunol"},{"key":"pone.0256980.ref041","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"M Roestenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0256980.ref042","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"KM Quinn","year":"2013","journal-title":"J Immunol"},{"key":"pone.0256980.ref043","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"KM Quinn","year":"2015","journal-title":"J Clin Invest"},{"key":"pone.0256980.ref044","article-title":"Progress with viral vectored malaria vaccines: A multi-stage approach involving \"unnatural immunity\"","author":"KJ Ewer","year":"2015","journal-title":"Vaccine"},{"key":"pone.0256980.ref045","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0256980.ref046","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"V Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"pone.0256980.ref047","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"D Weiskopf","year":"2020","journal-title":"Sci Immunol"},{"key":"pone.0256980.ref048","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"A Grifoni","year":"2020","journal-title":"Cell"},{"key":"pone.0256980.ref049","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s10038-020-0771-5","article-title":"Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2","volume":"65","author":"K Kiyotani","year":"2020","journal-title":"J Hum Genet"},{"key":"pone.0256980.ref050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000928","article-title":"Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial","volume":"8","author":"F Cappuccini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"pone.0256980.ref051","article-title":"Landscape and Selection of Vaccine Epitopes in SARS-CoV-2","author":"CC Smith","year":"2020","journal-title":"bioRxiv"},{"key":"pone.0256980.ref052","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1016\/j.vaccine.2017.07.054","article-title":"Vaccines against Ebola virus","volume":"36","author":"N Venkatraman","year":"2018","journal-title":"Vaccine"},{"key":"pone.0256980.ref053","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"MD Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0256980.ref054","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"K Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"pone.0256980.ref055","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia","volume":"377","author":"SB Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0256980.ref056","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"L Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"pone.0256980.ref057","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever","volume":"6","author":"GM Warimwe","year":"2016","journal-title":"Sci Rep"},{"key":"pone.0256980.ref058","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1016\/j.vaccine.2020.05.042","article-title":"Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes","volume":"38","author":"T Donnison","year":"2020","journal-title":"Vaccine"},{"key":"pone.0256980.ref059","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens8040231","article-title":"A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease","volume":"8","author":"RK Campos","year":"2019","journal-title":"Pathogens"},{"key":"pone.0256980.ref060","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1080\/22221751.2019.1620083","article-title":"Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection","volume":"8","author":"W Jia","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"pone.0256980.ref061","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection","volume":"9","author":"F Hartnell","year":"2018","journal-title":"Front Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T01:41:38Z","timestamp":1725759698000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256980"}},"subtitle":[],"editor":[{"given":"Stephen R.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256980","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]}}}